Matthew D Neal1, Joshua B Brown, Ernest E Moore, Joseph Cuschieri, Ronald V Maier, Joseph P Minei, Timothy R Billiar, Andrew B Peitzman, Mitchell J Cohen, Jason L Sperry. 1. *Division of General Surgery and Trauma, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; †Department of Surgery, Denver Health Medical Center and The University of Colorado Health Sciences Center, Denver; ‡Division of General Surgery and Trauma, Harborview Medical Center and the Department of Surgery, University of Washington, Seattle; §Division of Burn, Trauma, Critical Care, Department of Surgery, University of Texas Southwestern Medical Center, Dallas; and ¶Department of Surgery, University of California, San Francisco.
Abstract
OBJECTIVE: To determine whether prehospital nonsteroidal anti-inflammatory drug (NSAID) use may lead to a reduced incidence of trauma-induced coagulopathy (TIC) in severely injured patients. BACKGROUND: TIC is present in up to a quarter of severely injured trauma patients and is linked to worse outcomes after injury. Evidence linking TIC to inflammation has emerged; however, the mechanism behind this association is still under investigation. NSAIDs are commonly used anti-inflammatory drugs, but their effects on TIC and outcomes after injury are largely unexplored. METHODS: We performed a secondary analysis of the Inflammation and the Host Response to Injury Large Scale Collaborative Program (Glue Grant) data set. Prehospital medications and comorbidities were analyzed by logistic regression analysis for association with TIC as defined by laboratory (international normalized ratio >1.5) or clinical (transfusion >2 units of fresh frozen plasma or >1 pack of platelets in 6 hours) parameters. RESULTS: Prehospital NSIAD use was independently associated with a 72% lower risk of TIC and was the only medication among 15 analyzed to retain significance in the model. Stepwise logistic regression also demonstrated that preadmission use of NSAIDs was independently associated with a 66% lower risk of clinically significant coagulopathy. These findings were independent of comorbid conditions linked to NSAID use. CONCLUSIONS: NSAID use before admission for severe injury is associated with a reduced incidence of TIC. These findings provide further evidence to a potential leak between TIC and inflammation.
OBJECTIVE: To determine whether prehospital nonsteroidal anti-inflammatory drug (NSAID) use may lead to a reduced incidence of trauma-induced coagulopathy (TIC) in severely injured patients. BACKGROUND: TIC is present in up to a quarter of severely injured traumapatients and is linked to worse outcomes after injury. Evidence linking TIC to inflammation has emerged; however, the mechanism behind this association is still under investigation. NSAIDs are commonly used anti-inflammatory drugs, but their effects on TIC and outcomes after injury are largely unexplored. METHODS: We performed a secondary analysis of the Inflammation and the Host Response to Injury Large Scale Collaborative Program (Glue Grant) data set. Prehospital medications and comorbidities were analyzed by logistic regression analysis for association with TIC as defined by laboratory (international normalized ratio >1.5) or clinical (transfusion >2 units of fresh frozen plasma or >1 pack of platelets in 6 hours) parameters. RESULTS: Prehospital NSIAD use was independently associated with a 72% lower risk of TIC and was the only medication among 15 analyzed to retain significance in the model. Stepwise logistic regression also demonstrated that preadmission use of NSAIDs was independently associated with a 66% lower risk of clinically significant coagulopathy. These findings were independent of comorbid conditions linked to NSAID use. CONCLUSIONS: NSAID use before admission for severe injury is associated with a reduced incidence of TIC. These findings provide further evidence to a potential leak between TIC and inflammation.
Authors: C A Brandt; A M Deshpande; C Lu; G Ananth; K Sun; R Gadagkar; R Morse; C Rodriguez; P L Miller; P M Nadkarni Journal: AMIA Annu Symp Proc Date: 2003
Authors: G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher Journal: N Engl J Med Date: 2001-03-08 Impact factor: 91.245
Authors: K E Welty-Wolf; M S Carraway; D L Miller; T L Ortel; M Ezban; A J Ghio; S Idell; C A Piantadosi Journal: Am J Respir Crit Care Med Date: 2001-11-15 Impact factor: 21.405
Authors: Russell L Gruen; Karim Brohi; Martin Schreiber; Zsolt J Balogh; Veronica Pitt; Mayur Narayan; Ronald V Maier Journal: Lancet Date: 2012-09-22 Impact factor: 79.321
Authors: S N Faust; M Levin; O B Harrison; R D Goldin; M S Lockhart; S Kondaveeti; Z Laszik; C T Esmon; R S Heyderman Journal: N Engl J Med Date: 2001-08-09 Impact factor: 91.245
Authors: Debra L Miller; Karen Welty-Wolf; Martha Sue Carraway; Mirella Ezban; Andrew Ghio; Hagir Suliman; Claude A Piantadosi Journal: Am J Respir Cell Mol Biol Date: 2002-06 Impact factor: 6.914
Authors: Vahagn C Nikolian; Baihong Pan; Tomaz Mesar; Isabel S Dennahy; Patrick E Georgoff; Xiuzhen Duan; Baoling Liu; Xizi Wu; Michael J Duggan; Hasan B Alam; Yongqing Li Journal: Inflammation Date: 2017-08 Impact factor: 4.092
Authors: Sebastian Vogel; Rebecca Bodenstein; Qiwei Chen; Susanne Feil; Robert Feil; Johannes Rheinlaender; Tilman E Schäffer; Erwin Bohn; Julia-Stefanie Frick; Oliver Borst; Patrick Münzer; Britta Walker; Justin Markel; Gabor Csanyi; Patrick J Pagano; Patricia Loughran; Morgan E Jessup; Simon C Watkins; Grant C Bullock; Jason L Sperry; Brian S Zuckerbraun; Timothy R Billiar; Michael T Lotze; Meinrad Gawaz; Matthew D Neal Journal: J Clin Invest Date: 2015-11-09 Impact factor: 14.808